Trial Profile
DAS181 for COVID-19: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Oplunofusp (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Ansun Biopharma
- 07 Aug 2020 Study design changed from Parallel Assignment to Sequential Assignment. Number of arms changed from 2 to 3. Experimental arm: DAS181 q.d.+ standard local care for COVID-19 added to study protocol. Primary and secondary outcome measures amended. Study Phase changed from Phase II/III to Phase II.
- 07 Aug 2020 Planned End Date changed from 31 Oct 2020 to 30 Nov 2020.
- 07 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Sep 2020.